OncoMatch

OncoMatch/Clinical Trials/NCT06891157

Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes

Is NCT06891157 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Chidamide plus R-CHOP for chidamide.

Phase 2RecruitingThe First Affiliated Hospital with Nanjing Medical UniversityNCT06891157Data as of Jun 2026Location: China

Treatment: Chidamide plus R-CHOPEvaluation of the Safety and Efficacy of CR-CHOP Treatment in Newly Diagnosed Double-Expressor DLBCL with Other Molecular Subtypes

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Chidamide plus R-CHOP

Cancer type

Diffuse Large B-Cell Lymphoma

Non-Hodgkin Lymphoma

Biomarker criteria

Required: BCL2 overexpression (≥ 50%)

Required: MYC overexpression (≥ 40%)

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: lymphoma treatment

Lab requirements

Kidney function

serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 35 mL/min as calculated by the Cockcroft-Gault formula

Liver function

total bilirubin (TBIL) ≤ 3 × ULN; ALT and AST ≤ 5 × ULN; ALP ≤ 5 × ULN

Adequate hepatic function is defined as: total bilirubin (TBIL) ≤ 3 times the upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤5 × ULN; alkaline phosphatase (ALP) ≤ 5 × ULN; serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 35 mL/min as calculated by the Cockcroft-Gault formula

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06891157 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

Does this trial require BCL2?

Yes, BCL2 overexpression is a required biomarker for enrollment.

Does this trial require MYC?

Yes, MYC overexpression is a required biomarker for enrollment.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify